Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 Treatment: A Randomized Controlled Study
Abd-Elsalam et al.,
Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 Treatment: A Randomized Controlled Study,
Journal of Medical Virology, doi:10.1002/jmv.27122
RCT 164 hospitalized patients in Egypt showing lower mortality and shorter hospitalization, but without statistical significance. There were no serious adverse effects. Authors suggest the low dosage may have resulted in lower efficacy than other trials, and recommend increased dosage in future trials. For other concerns see
[onlinelibrary.wiley.com]. Time from symptom onset is not specified.
risk of death, 25.0% lower, RR 0.75, p = 0.70, treatment 3 of 82 (3.7%), control 4 of 82 (4.9%), NNT 82, odds ratio converted to relative risk, logistic regression, primary outcome.
|
risk of mechanical ventilation, no change, RR 1.00, p = 1.00, treatment 3 of 82 (3.7%), control 3 of 82 (3.7%).
|
hospitalization time, 19.6% lower, relative time 0.80, p = 0.09, treatment 82, control 82.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Abd-Elsalam et al., 2 Jun 2021, Randomized Controlled Trial, Egypt, peer-reviewed, 16 authors, dosage 12mg days 1-3.
Abstract: Received: 29 May 2021
|
Accepted: 31 May 2021
DOI: 10.1002/jmv.27122
RESEARCH ARTICLE
Clinical study evaluating the efficacy of ivermectin in
COVID‐19 treatment: A randomized controlled study
Sherief Abd‐Elsalam1
| Rasha A. Noor2
| Rehab Badawi1
| Mai Khalaf1 |
Eslam S. Esmail1 | Shaimaa Soliman3 | Mohamed S. Abd El Ghafar4 |
Mohamed Elbahnasawy5
| Ehab F. Moustafa6 | Sahar M. Hassany6 |
Mohammed A. Medhat6 | Haidi Karam‐Allah Ramadan6 | Maii A. S. Eldeen7
Mohamed Alboraie8 | Ahmed Cordie9 | Gamal Esmat9
1
Department of Tropical Medicine and
Infectious diseases, Faculty of Medicine,
Tanta University, Tanta, Egypt
|
Abstract
Researchers around the world are working at record speed to find the best ways to
2
Department of Internal Medicine, Faculty of
Medicine, Tanta University, Tanta, Egypt
3
Department of Public health and Community
Medicine, Faculty of Medicine, Menoufia
University, Menoufia, Egypt
4
Department of Anesthesia, Surgical Intensive
Care, and Pain Medicine, Faculty of Medicine,
Tanta University, Tanta, Egypt
5
Department of Emergency Medicine and
traumatology, Faculty of Medicine, Tanta
University, Tanta, Egypt
6
Department of Tropical Medicine and
Gastroenterology, Faculty of Medicine, Assiut
University, Assiut, Egypt
7
Department of Microbiology and
Immunology, Tanta University, Tanta, Egypt
8
Department of Internal Medicine, Al‐Azhar
University, Cairo, Egypt
9
Department of Endemic Medicine, Kasr
Alainy School of Medicine, Cairo University,
Cairo, Egypt
Correspondence
Sherief Abd‐Elsalam, Department of Tropical
Medicine and Infectious Diseases, Faculty of
Medicine, Tanta University, El‐Giash St,
31527 Tanta, Egypt.
Email: sherif.abdelbaky@med.tanta.edu.eg
treat and prevent coronavirus disease 2019 (COVID‐19). This study aimed to
evaluate the efficacy of ivermectin for the treatment of hospitalized mild to moderate COVID‐19 infected patients. This was a randomized open‐label controlled
study that included 164 patients with COVID‐19. Patients were randomized into
two groups where Group 1 (Ivermectin group) included patients who received
ivermectin 12 mg once daily for 3 days with standard care and Group 2 (control
group) included patients who received standard protocol of treatment alone for 14
days. The main outcomes were mortality, the length of hospital stay, and the need
for mechanical ventilation. All patients were followed up for 1 month. Overall, 82
individuals were randomized to receive ivermectin plus standard of care and 82 to
receive standard of care alone. Patients in the ivermectin group had a shorter length
of hospital stay (8.82 ± 4.94 days) than the control group (10.97 ± 5.28 days), but
this was not statistically significant (p = 0.085). Three patients (3.7%) in each group
required mechanical ventilation (p = 1.00). The death rate was three patients in the
ivermectin group (3.7%) versus four patients (4.9%) in the control group without any
significant difference between the two groups (p = 1.00). Although there was no
statistically significant difference in any endpoints by ivermectin doses (12 mg/day
for 3 days); there was an observed trend to reducing hospital stay in the ivermectin‐
treated group.
KEYWORDS
COVID‐19, chloroquine, ivermectin, mortality, treatment
1
| INTRODUCTION
in Wuhan City, Hubei Province, China. It was originally reported to the
World Health Organization (WHO) on December 31, 2019. The WHO
Coronavirus disease 2019 (COVID‐19) is caused by a novel..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit